News
Top News | Zhang Haijun, Director of the Drug Production Division at the Provincial Drug Administration Bureau, and his delegation visit Wanbangde for research.
Date:
07 Nov,2023
On November 2, 2023, during the 19th Taizhou Pharmaceutical Regulatory Salon event, Zhang Haijun, Director of the Drug Production Division at the Provincial Drug Administration Bureau, and his delegation visited Wanbangde Pharmaceutical Group for a research visit. They were accompanied by Ye Xingfu, a third-level researcher at the Taizhou Municipal Bureau; Chen Bin, Director of the Drug Production Division; Tong Qingbo, Secretary of the Party Committee and Director of the Wenling Municipal Bureau; and Zhu Keqiang, Member of the Party Committee and Deputy Director of the Wenling Municipal Bureau. Joining them was Zhao Shouming, Chairman of Wanbangde Group, along with Lin Hong, Vice General Manager of Wanbangde Pharmaceutical Group.
Director Zhang and his delegation toured the company's pharmaceutical exhibition hall firsthand. During the visit, CEO Zhao provided a detailed overview of Wanbangde Pharmaceutical's and its medical device division's current production and operational status, as well as their development journey, with a particular focus on the core flagship products driving both key industries.
At the symposium, Chairman Zhao provided a detailed overview of Wanbangde Group’s industrial layout across its four key sectors, including its R&D pipeline and product roadmap. He particularly highlighted the company’s strategic product positioning in its exclusive pharmaceutical offerings, as well as the future growth prospects for the medical device business. Additionally, he briefly outlined the Group’s recent “50100 Plan” aimed at advancing its two major pharmaceutical industries. Meanwhile, the head of Wenling Innovative Biotech gave a concise update on the current status of ongoing project construction.
During the symposium, Director Zhang and his team provided detailed explanations and guidance on challenges related to drug manufacturing license approvals, drug registration, traceability system development, contract manufacturing, and policy support for traditional Chinese medicine.
Finally, Director Zhang expressed full appreciation for Wanbangde Pharmaceutical’s strategic layout in the greater healthcare industry, and noted:
● We must strengthen communication between government and enterprises, leveraging demand-driven approaches and institutional safeguards to jointly accelerate the commercialization of scientific and technological achievements.
● We must continuously improve the quality traceability mechanism to ensure that pharmaceutical products remain safe, effective, and fully controllable throughout their entire lifecycle. Pharmaceutical traceability through digitalization serves as a powerful enabler of regulatory efficiency—allowing for deeper insights that lead to more thorough analysis of product distribution channels, faster responses to random inspections, and more standardized, transparent, and legally compliant data management. By leveraging information technology to guide pharmaceutical quality and safety, we can safeguard public health and drive high-quality growth in Taizhou’s thriving pharmaceutical and healthcare industry.
Related Recommendations